화학공학소재연구정보센터
Biochemical and Biophysical Research Communications, Vol.453, No.3, 309-315, 2014
Thioaptamers targeting dengue virus type-2 envelope protein domain III
Thioaptamers targeting the dengue-2 virus (DENV-2) envelope protein domain III (EDIII) were developed. EDIII, which contains epitopes for binding neutralizing antibodies, is the putative host-receptor binding domain and is thus an attractive target for development of vaccines, anti-viral therapeutic and diagnostic agents. Thioaptamer DENTA-1 bound to DENV-2 EDIII adjacent to a known neutralizing antibody binding site with a dissociation constant of 154 nM. Published by Elsevier Inc.